Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: the COMplement inhibition in Myo-cardial infarction treated with Angioplasty (COMMA) trial - Granger, CB; Mahaffey, KW; Weaver, WD (Circulation, 2003)
et al.